Microsoft word - mall_publikaitonsliste.doc

Prof. Dr. V. Mall
Publikationsliste
in print

1. Jung NH, Delvendahl I, Pechmann A, Gleich B, Gattinger N, Siebner HR, Mall V. Transcranial
magnetic stimulation with a half-sine wave pulse elicits direction-specific effects in human motor cortex. BMC Neuroscience 2. Jung NH, Janzarik WG, Delvendahl I, Münchau A, Biscaldi M, Mainberger F, Bäumer T, Rauh R, Mall V. Impaired induction of long-term potentiation-like plasticity in patients with high-fuctioning
autism and Asperger syndrome. Dev Med & Child Neurol.

3. Delvendahl I, Jung NH, Kuhnke NG, Mainberger F, Ziemann U, Mall V. Plasticity of motor
threshold and motor-evoked potential amplitude – a model of intrinsic and synaptic plasticity in human motor cortex? Brain Stimul. [Epub ahead of print]
4. Delvendahl I, Lindemann H, Heidegger T, Normann C, Ziemann U, Mall V. Effects of lamotrigine
on human motor cortex plasticity. Clin Neurophysiol. [Epub ahead of print]
5. Poretti A, Mall V, Smitka M, Grunt S, Risen S, Toelle SP, Benson JE, Yoshida S, Jung NH,
Tinschert S, Neuhann TM, Rauch A, Steinlin M, Meoded A, Huisman TA, Boltshauser E. Macrocerebellum: Significance and pathogenic considerations. Cerebellum [Epub ahead of print] 2012
6. Blaschek A, Van’s Gravesande KS, Heinen F, Pritsch M, Mall V, Calabrese P (2012).
Neuropsychological aspects of childhood multiple sclerosis: an overview. Neuropediatrics 43 (4): 176-83.
7. Groppa S, Oliviero A, Eisen A, Quartarone A, Cohen LG, Mall V, Kaelin-Lang A, Mima T, Rossi S,
Thickbroom GW, Rossini PM, Ziemann U, Valls-Solé J, Siebner HR (2012). A practical guide to diagnostic transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol. 123 (5): 858-82.
8. Pechmann A, Delvendahl I, Bergmann TO, Ritter C Hartwigsen G, Gleich B, Gattinger N, Mall V,
Siebner HR (2012). The number of full-sine cycles per pulse influences the efficacy of multicycle transcranial magnetic stimulation. Brain Stimul. 5 (2): 148-54.
2011
9. Jung NH, Heinen F, Westhoff B, Doederlein L, Reissig A, Berweck S, Linder-Lucht M, Schandelmaier S, Mall V (2011). Hip lateralisation in children with bilateral spastic cerebral palsy
treated with botulinum toxin type A: a 2-year follow-up. Neuropediatrics 42 (1): 18-23.
10. Delvendahl I, Kuhnke NG, Jung NH, Mainberger F, Cronjaeger M, Unterrainer J, Hauschke D,
Mall V (2011). The time course of motor cortex plasticity after spaced motor practice. Brain
Stimul. 4 (3): 156-64.

2010


11. Delvendahl I, Jung NH, Mainberger F, Kuhnke NG, Cronjaeger M, Mall V (2010). Occlusion of
bidirectional plasticity by preceding low-frequency stimulation in the human motor cortex. Clin Neurophysiol. 121 (4): 594-602. 12. Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, Andersen GL, Aydin R, Becher JG, Bernert G, Caballero IM, Carr L, Valayer EC, Desiato MT, Fairhurst C,
Filipetti P, Hassink RI, Hustedt U, Jozwiak M, Kocer SI, Kolanowski E, Krägeloh-Mann I, Kutlay S,
Mäenpää H, Mall V, McArthur P, Morel E, Papavassiliou A, Pascual-Pascual I, Pedersen SA,
Plasschaert FS, van der Ploeg I, Remy-Neris O, Renders A, Di Rosa G, Steinlin M, Tedroff K,
Valls JV, Viehweger E, Molenaers G (2010). The updated European Consensus 2009 on the use
of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 14 (1): 45-66.

13. Jung NH, Delvendahl I, Kuhnke NG, Hauschke D, Stolle S, Mall V (2010). Navigated transcranial
magnetic stimulation does not decrease the variability of motor-evoked potentials. Brain Stimul. 3 (2): 87-94. 2009
14. Walther M, Juenger H, Kuhnke N, Marko Wilke M, Brodbeck V, Berweck S, Staudt M, Mall V
(2009). Motor cortex plasticity in ischemic perinatal stroke - a transcranial magnetic stimulation
and functional MRI study. Pediatr Neurol. 41 (3):171-8.
IF 1,375

15. Walther M, Berweck S, Schessl J, Linder-Lucht M, Fietzek UM, Glocker FX, Heinen F, Mall V
(2009). Maturation of inhibitory and excitatory motor cortex pathways in children. Brain Dev. 31
(7):562-7.
IF 1,464

16. Haug V, Linder-Lucht M, Zieger B, Korinthenberg R, Mall V, Mader I (2009). Unilateral venous
thalamic infarction in a child mimicking a thalamic tumor. J Child Neurol, 24 (1):105-9. 17. Hodapp M, Vry J, Mall V, Faist M (2009). Changes in soleus H-reflex modulation after treadmill
training in children with cerebral palsy. Brain 132 (Pt 1): 37-44.
IF 8,568

2008
18. Kuhnke N, Juenger H, Walther M, Berweck S, Mall V, Staudt M (2008). Do patients with
congenital hemiparesis and ipsilaterial corticospinal projections respond differently to constraint-induced movement therapy? Dev Med Child Neurol. 50 (12): :898-903.
19. Vry J, Linder-Lucht M, Berweck S, Bonati U, Hodapp M, Faist M, Mall V (2008). Altered Cortical
inhibitory function in children with spastic diplegia: A TMS study. Exp. Brain Res. 186 (4): 611-8.
20. Walther M, Kuhnke N, Schessl J, Delvendahl I, Jung N, Kreml D, Ziemann U, Mall V (2008).
Deafferentation of neighbouring motor cortex areas does not further enhance saturated practice-dependent plasticity in healthy adults. Clin Neurophysiol, 119 (4):886-91.
21. Berweck S, Walther M, Brodbeck V, Wagner N, Koerte I, Henschel V, Juenger H, Staudt M, Mall
V (2008). Abnormal motor cortex excitability in congenital stroke. Pediatr Res. 63 (1):84-8.


2007
22. Hodapp M, Klisch C, Mall V, Vry J, Berger W, Faist M (2007). Modulation of soleus H-reflexes
during gait in children with cerebral palsy. J Neurophysiol. 98 (6):3263-8.
23. Juenger H, Linder-Lucht M, Walther M, Berweck S, Mall V, Staudt M (2007). Cortical
neuromodulation by constraint-induced movement therapy in congenital hemiparesis – an FMRI study. Neuropediatrics 38 (3):130-6. 24. Linder-Lucht M, Othmer V, Walther M, Vry J, Michaelis U, Stein S, Weissenmayer H, Korinthenberg R, Mall V, Gross Motor Function Measure-Traumatic Brain Injury Study Group
(2007). Validation of the Gross Motor Function Measure for use in children and adolescents with
traumatic brain injuries. Pediatrics 120 (4):e880-6.

25. Hodapp M, Klisch C, Berger W, Mall V, Faist M (2007). Modulation of soleus H-reflexes during
gait in healthy children. Exp Brain Res. 178 (2):252-60.
2006 und früher
26. Schüle R, Holland-Letz T, Klimpe S, Kassubek J, Klopstock T, Mall V, Otto S, Winner B, Schöls L
(2006). The Spastic Paraplegia Rating Scale (SPRS): a reliable and valid measure of disease severity. Neurology 67 (3):430-4. 27. Mall V, Heinen F, Siebel A, Bertram C, Hafkemeyer U, Wissel J, Berweck S, Haverkamp F, Nass
G, Döderlein L, Breitbach-Faller N, Schulte-Mattler W, Korinthenberg R (2006). Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev Med Child Neurol. 48 (1):10-3.
28. Mall V, Linder M, Herpers M, Schelle A, Mendez-Mendez J, Korinthenberg R, Schumacher M,
Spreer J (2005). Recruitment of the sensorimotor cortex -a developmental FMRI study. Neuropediatrics 36 (6):373-9. 29. Herrmann J, Geth K, Mall V, Bigalke H, Schulte-Mönting J, Linder M, Kirschner J, Berweck S,
Korinthenberg R, Heinen F, Fietzek UM (2004). Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol. 55 (5):732-5.
30. Mall V, Berweck S, Fietzek HM, Glocker FX, Oberhuber U, Walther M, Schessl J, Schulte-Mönting
J, Korinthenberg R, Heinen F (2004). Low level of intracortical inhibition in children shown by transcranial magnetic stimulation. Neuropediatrics 35 (2): 120-5.
31. Kirschner J, Moll GH, Fietzek UM, Heinrich H, Mall V, Heinen F, Rothenberger A (2003).
Methylphenidate enhances both intracortical inhibition and facilitation in healthy adults. Pharmacopsychiatry 36 (2):79–82. 32. Mall V, Glocker FX, Fietzek UM, Heinen F, Berweck S, Korinthenberg R, Rösler KM (2001).
Inhibitory conditioning stimulus in transcranial magnetic stimulation reduces the number of excited spinal motor neurons. Clin Neurophysiol. 112 (10):1810-3. 33. Mall V, Glocker FX, Frankenschmidt A, Gordjani N, Heinen F, Brandis M, Korinthenberg R (2001).
Treatment of neuropathic bladder using botulinum toxin A in a 1-year-old child with myelomeningocele. Pediatr Nephrol. 16 (12):1161-2. 34. Linder M, Schindler G, Michaelis U, Stein S, Kirschner J, Mall V, Berweck S, Korinthenberg R,
Heinen F (2001). Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure. Eur J Neurol. 8 Suppl 5: 120-6.
35. Mall V, Heinen F, Uhl M, Wellens E, Korinthenberg R (2000). CNS lipoma in patients with
epidermal nevus syndrome. Neuropediatrics 31 (4):175-9. 36. Mall V, Heinen F, Kirschner J, Linder M, Stein S, Michaelis U, Bernius P, Lane M, Korinthenberg
R (2000). Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure. J Child Neurol. 15 (4):214-7. 37. Herrmann J, Mall V, Bigalke H, Geth K, Korinthenberg R, Heinen F (2000). Secondary non-
response due to development of neutralising antibodies to botulinum toxin A during treatment of children with cerebral palsy. Neuropediatrics 31 (6):333-4. 38. Mullikin JC, Hunt SE, Cole CG, Mortimore BJ, Rice CM, Burton J, Matthews LH, Pavitt R, Plumb RW, Sims SK, Ainscough RM, Attwood J, Bailey JM, Barlow K, Bruskiewich RM, Butcher PN,
Carter NP, Chen Y, Clee CM, Coggill PC, Davies J, Davies RM, Dawson E, Francis MD, Joy AA,
Lamble RG, Langford CF, Macarthy J, Mall V, Moreland A, Overton-Larty EK, Ross MT, Smith LC,
Stweward CA, Sulson JE, Tinsley EJ, Turney KJ, Willey DL, Wilson GD, McMurray AA, Dunham I,
Rogers J, Bentley DR (2000). An SNP map of human chromosome 22. Nature 407 (6803): 516-
20.
39. Wissel J, Müller J, Heinen F, Mall V, Sojer M, Ebersbach G, Poewe W (1999). Prospektive
multizentrische Untersuchung einer einmaligen Botulinum Toxin Behandlung bei 204 Patienten mit akuter und chronischer Spastizität. Wien Klin Wochenschr. 111 (20):837-42. 40. Mall V, Thomas KB, Sauter S, Niemeyer CM, Sutor AH (1999). Effect of glucocorticoids, E. coli-
and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia. Klin Pädiatr. 211 (4):205-10. 41. Heinen F, Mall V, Rückauer KD, Greiner P, Korinthenberg R (1999). Lack of response to
botulinum toxin A in patients with hypertrophic pyloric stenosis. Eur J Pediatr. 158 (5):436. 42. Heinen F, Linder M, Mall V, Kirschner J, Korinthenberg R (1999). Adductor spasticity in children
with cerebral palsy and treatment with botulinum toxin A – the parents’ view of functional outcome. Eur J Neurol. 6:47-50. 43. Sutor AH, Mall V, Thomas KB (1999). Bleeding and thrombosis in children with acute
lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol. Klin Pädiatr. 211 (4): 201-4. 44. Heinen F, Kirschner J, Fietzek UM, Glocker FX, Mall V, Korinthenberg R (1999). Absence of
transcallosal inhibition in adolescents with diplegic cerebral palsy: Muscle Nerve 22 (2):255-7. 45. Mall V, Heinen F, Linder M, Philipsen A, Korinthenberg R (1997). Treatment of cerebral palsy with
botulinum toxin A: functional benefit and reduction of disability. Three case reports. Pediatr Rehabil. 1 (4):235-7. 46. Heinen F, Wissel J, Philipsen A, Mall V, Leititis JU, Schenkel A, Stücker R, Korinthenberg R
(1997). Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A. Neuropediatrics 28 (6):307-3. 47. Heinen F, Petersen H, Fietzek UM, Mall V, Schulte-Mönting J, Korinthenberg R (1997).
Transcranial magnetic stimulation in patients with Rett syndrome: preliminary results. Eur Child Adoles Psychiatry 6 Suppl 1: 61-3. Eingeladene Reviews, Übersichtsarbeiten
1. Dan B, Motta F, Vles JS, Vloeberghs M, Becher JG, Eunson P, Gautheron V, Lütjen S, Mall V,
Pascual-Pascual SI, Pauwels P, Rǿste GK (2010). Consensus on the appropriate use of intrathecal baclofen (ITB) therapy in paediatric spasticity. Eur J Paediatr Neurol. 14 (1): 19-28.
2. Garvey MA, Mall V (2008). Transcranial magnetic stimulation in children. Clin Neurophysiol. 119

3. Mall V (2007). Constraint Induced Movement Therapy. Kinderärztl Prax. 78 (6):306-10.
4. Mall V. (2007) Beiträge der klinischen Neurophysiologie zum Verständnis der Entwicklung des
Gehirns. Monatsschr Kinderheilkd. 155 (6): 514-18.
5. Heinen F, Döderlein L, Hustedt U, Fietzek UM, Berweck S, Schröder S, Mall V, Wiedenhöfer B,
Sprinz A, Benecke R, Behrens K-E, Wissel J, Krägeloh-Mann, I (2007). Botulinumtoxin für Kinder mit Zerebralparese: 10 Punkte-Tabelle. Monatsschr Kinderheilkd. 155 (6):537-43.
6. Mall V (2006). Therapieforschung bei spastischen Bewegungsstörungen nach frühen
Hirnläsionen. Neuropädiatrie in Klinik und Praxis 5(3):92-100.
7. Mall V (2006). Botulinumtoxin-Therapie im Langzeitverlauf. Neuropädiatrie in Klinik und Praxis 5

8. Mall V, Berweck S, Kirschner J, Hermann J, Schelle A, Linder M, Michaelis U, Stein S,
Korinthenberg, R, Heinen, F (2001): Die Therapie spastischer Berwegungsstörungen im Kindesalter mit Botulinumtoxin A. Klin Neurophysiol. 32 (4) :218-24.
9. Kirschner J, Berweck S, Mall V, Korinthenberg R, Heinen, F (2001). Botulinum toxin treatment in
cerebral palsy: evidence for a new treatment option. J Neurol. 248 Suppl 1: 28-30. Review. 10. Kirschner J, Berweck S, Mall V, Korinthenberg R, Heinen, F (2001). Botulinumtoxin – Neue
Therapiemöglichkeit für Kinder mit CP. Deutsches Ärzteblatt 50:2840-2845.
11. Mall V, Berweck S, Heinen F (2004). Transkranielle Magnetstimulation im Kindesalter. Klin

12. Heinen F, Mall V, Wissel J, Bernius P, Stücker R, Linder M, Korinthenberg R (1997). Botulinum
Toxin A: neue Möglichkeiten in der Behandlung spastischer Bewegungsstörungen. Monatsschr Kinderheilkd. 145 (10): 1088-92. Buchbeiträge, Buchherausgabe, sonstige Publikationen
1. Mall V, Kerr Graham H (2009). Die Zerebralparese. In: Korinthenberg R, Panteliadis ChP, Hagel
Ch (Hrsg.). Neuropädiatrie – Evidenzbasierte Therapie, pp187-204, Urban & Fischer, München 2009. 2. Storm van’s Gravesande K, Korinthenberg R, Mall V (2009).Therapiemanagement bei Kindern mit
MS an der Universitäts-Kinderklinik Freiburg. Klin Pädiatr. 221 (2): A74. 3. Heinen F, Böhmer J, Hufschmidt A, Berweck S, Christen HJ, Fietzek U, Kieslich M, Krieg S, Mall
V, Müller-Felber W (Hrsg.): Pädiatrische Neurologie. Diagnose und Therapie mit Paediatric
Clinical Scouts. Kohlhammer, Stuttgart 2009.

4. Schessl J, Mall V, Verlthoven V, Korinthenberg R (2007). Ascites and weight loss with an
intracranial mass. Monatsschr Kinderheilkd. 155 (6):503-4.
5. Linder-Lucht M, Kirschner J, Herrmann J, Geth K, Korinthenberg R, Berweck S, Heinen F, Mall V
(2006). Why do children with cerebral palsy discontinue therapy with botulinum toxin A? Dev Med
Child Neurol. 48 (4):319-20.
IF: 1,79

6. Mall V, Heinen F, Fritsch U, Franck U, Dietz B, Brockmann K, Voss W, Naß G, Feldmann E,
Korinthenberg R. Multizentrische Studie zur Behandlung des Adduktorenspasmus mt Botulinum Toxin A: 1 Jahres Follow-up. In: Aksu F (Hrsg), Aktuelle Neuropädiatrie, pp626-630, Novartis Pharma Verlag, Nürnberg 2002.
7. Herrmann J, Mall V, Bigalke H, Geth K, Linder M, Kirschner J, Berweck S, Korinthenberg R,
Heinen F. Neutralisierende Antikörper und sekundäre Non-response in der Behandlung der Cerebralparese mit Botulinum Toxin A. In: Aksu F (Hrsg), Aktuelle Neuropädiatrie, pp635-638, Novartis Pharma Verlag, Nürnberg 2002.
8. Schelle A, Oberhuber U, Mall V, Fietzek U, Beweck S, Glocker FX, Korinthenberg R, Heinen F.
Die corticomotoneuronale Bahn: Beiträge der Transkraniellen Magnetstimulation zur Pathophysiologie der spastischen Diparese. In: Aksu F (Hrsg), Aktuelle Neuropädiatrie, pp400-403, Novartis Pharma Verlag, Nürnberg 2002.
9. Stein S, Michaelis U, Kirschner J, Linder M, Mall V, Heinen F, Korinthenberg R.
Therapieevaluation mit der Gross Motor Function Measure bei Kindern mit Cereralparese. In: Aksu F (Hrsg), Aktuelle Neuropädiatrie, pp739-744, Novartis Pharma Verlag, Nürnberg 2002. 10. Mall V, Berweck S. Botulinumtoxin A – Stand der Forschung. In: Heinen F, Bartens W (Hrsg.) Das Kind und die Spastik, S. 135-44, Hans Huber, Bern 2001.
11. Linder M, Geth K, Herrmann J, Kirschner J, Mall V, Heinen F, Korinthenberg R. Gründe für die
Beendigung der Therapie mit Botulinum Toxin A bei Kindern mit Cerebralparese: eine retrospektive Analyse von 125 Patienten. In: Aksu F (Hrsg), Aktuelle Neuropädiatrie, pp631-634, Novartis Pharma Verlag, Nürnberg 2002.
12. Mall V. Hip dislocation – Clinical data, outcome, dose and safety. In: Stephanie U (Hrsg), Aktuelle
Neuropädiatrie, pp321-325, Novartis Pharma Verlag, Nürnberg 2001.
13. Mall V, Heinen F, Schulte-Mattler W, Schauseil-Zipf U, Wissel J, Dietz B, Voss W, Klowat B,
Göhlich-Ratmann G, Breitbach-Faller N, Döderlein L, Korinthenberg R. Multizentrische Studie zur Behandlung des Adduktorenspasmus mit Botulinum Toxin A. Das ABo-Projekt: Methoden und erste Zwischenergebnisse. In: Millner M (Hrsg): Aktuelle Neuropädiatrie 1999, pp277-282, Novartis Pharma Verlag, Nürmberg 2000. 14. Mall V, Kirschner, J, Heinen, F, Linder, M, Stein, S, Michaelis, U, Bernius, P, Korinthenberg , R.
Gross Motor function measure for therapy evaluation in children treated with Botulinum toxin A. In: Perat MV (Hrsg): New developments in Child Neurology, pp247-250, Monduzzi Editore S.p.A., Bologna 1998
15. Heinen F, Philipsen A, Mall V, Korinthenberg, R. Cerebrale Bewegungsstörungen: Additive
Behandlungsmöglichkeiten durch lokale Injektion von Botulinum-Toxin A. In: Viebrock H, Brandl U (Hrsg): Neurophysiologie cerebraler Bewegungsstörungen und Bobath-Therapie, Bremen, pp123-126, 1997.
16. Heinen F, Mall V, Korinthenberg R (1997). Torticollis spasmodicus. Monatsschr Kinderheilkd. 145

Source: http://www.kinderzentrum-muenchen.de/fileadmin/user_upload/Oeffentlichkeitsarbeit/Inhalte_Prof_Mall/Mall_Publikaitonsliste.pdf

Diabetes melito

Diabetes Melito 1 – Definição: O diabetes melito é uma síndrome de etiologia múltipla decorrente da falta de insulina e/ou da incapacidade da insulina exercer adequadamente seus efeitos. Caracteriza-se por hiperglicemia crônica com distúrbios do metabolismo dos carboidratos, lipídeos e proteínas. A longo prazo, se acompanha de disfunção e falência de vários órgãos, por

bne-a-ms5.retain.aarnet.edu.au

Title Differential Binding Analysis of ChIP-Seq peak dataRory Stark<rory.stark@cancer.org.uk>, Gordon Brown <gordon.brown@cancer.org.uk>Maintainer Rory Stark<rory.stark@cancer.org.uk>Description Compute differentially bound sites from multiple ChIP-seq experiments using affin-ity (quantitative) data. Also enables occupancy (overlap) analysis and plotting functions. biocViews

Copyright © 2014 Medical Pdf Articles